Comment on ‘Pembrolizumab hybrid dosing is non-inferior to flat dosing in advanced non-small cell lu...
Comment on ‘Pembrolizumab hybrid dosing is non-inferior to flat dosing in advanced non-small cell lung cancer: a real-world, retrospective bicenter cohort study’
About this item
Full title
Author / Creator
Publisher
England: BMJ Publishing Group Ltd
Journal title
Language
English
Formats
Publication information
Publisher
England: BMJ Publishing Group Ltd
Subjects
More information
Scope and Contents
Contents
Correspondence to Dr Xudong Zhu; xdzhu@cmu.edu.cn ; XudongZhu@uky.edu The study by Smeenk et al provides valuable insights into optimizing pembrolizumab dosing strategies for advanced non-small cell lung cancer (NSCLC) through a hybrid weight-based regimen.1 Their findings suggest non-inferior survival outcomes and significant cost reductions compa...
Alternative Titles
Full title
Comment on ‘Pembrolizumab hybrid dosing is non-inferior to flat dosing in advanced non-small cell lung cancer: a real-world, retrospective bicenter cohort study’
Authors, Artists and Contributors
Author / Creator
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_doaj_primary_oai_doaj_org_article_d285e419fdca4c09ae7b999d943c8dd1
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_d285e419fdca4c09ae7b999d943c8dd1
Other Identifiers
ISSN
2051-1426
E-ISSN
2051-1426
DOI
10.1136/jitc-2025-011845
